Realyze Intelligence, created by UPMC in 2021 to apply artificial intelligence and natural language processing to datasets for treatment of cancer and chronic conditions, is working with Memorial Sloan Kettering Cancer on a new analytics collaboration.
WHY IT MATTERS
MSK’s Innovation Hub is working with Realyze to mine real-world data from the unstructured text of patient electronic health records to help improve cancer research and treatment.
MSK, which has a financial stake in Realyze, is using its platform-as-service capabilities to analyze longitudinal patient records and other datasets to extract information to help scientists and clinicians further their research and develop new cancer treatment models using disease-specific patient summaries.
Realyze’s natural language understanding can gain insights from unstructured text notes in patients’ EHRs faster and more efficiently – enabling actionable information to help oncologists and other clinicians make more informed and timely treatment decisions.
“Our goal is to make it easier and more efficient for health systems and cancer centers to understand and use their data to improve patient care,” Realyze Intelligence CEO Aaron Brauser said in a statement. “By working with MSK Innovation Hub, we have the opportunity to improve the care and quality of life for patients undergoing cancer treatments by ensuring their health care team has the most accurate and meaningful information.”
THE LARGER TREND
This past month, we reported that researchers at the UPMC Hillman Cancer Center are using Realyze Intelligence technology to understand the utility of sentinel lymph node biopsy, or SLNB, for early-stage breast cancer patients under age 70.
“By using the Realyze platform rather than a cancer registry, we can quickly and efficiently extract a large amount of data in real time,” Dr. Adrian Lee, director of the UPMC/University of Pittsburgh Institute of Precision Medicine and breast cancer investigator, said in announcing the unpublished research study.
A HIMSSCast episode from this past March, meanwhile, shows how the Memorial Sloan Kettering Alliance is advancing cancer research with precision oncology in clinical trials.
ON THE RECORD
“We look forward to working with Realyze through this innovative collaboration,” John Philip, senior director of MSK’s Research Support Platform, said in a statement. “The data within the clinical notes of patients’ medical records may unlock important scientific and clinical correlations. Being able to pull this information in a more efficient way could help connect patients with important resources and help physicians develop the most optimal care plans for their patients.”
Email the writer: [email protected]
Healthcare IT News is a HIMSS publication.
Source: Read Full Article